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ABSTRACT
Objectives: Findings from the largest randomized phase
III trial in patients with unresectable malignant pleural
mesothelioma (EMPHACIS study; n = 448) were used to
examine the cost-effectiveness of pemetrexed plus cisplatin
therapy versus cisplatin monotherapy in patients with the
disease. The cost-effectiveness of pemetrexed/cisplatin versus
alternative treatments was also examined.
Methods: Two cost-effectiveness analyses were designed to
model best survival outcome over time for a number of patient
cohorts. First, trial-based patient-level data were utilized and
resource use was costed for the study arm and comparator. A
second cost-effectiveness analysis then compared the mean
costs and outcomes associated with pemetrexed/cisplatin with
the most commonly used (unlicensed) regimens in the United
Kingdom—mitomycin-C, vinblastine, and cisplatin (MVP);
vinorelbine; and active symptom control—using trial-based
data and data extrapolated from a review of the literature.
Results: The total pemetrexed/cisplatin cost per patient
varied between £8779 and £9020 for all cohorts studied in
model 1. Average life-years gained per patient were between
0.20 and 0.28. Quality-adjusted life-years, based on mean
and median survival, ranged from 0.13 to 0.31. Incremental
cost per life-year gained and quality-adjusted life-year
ratios, using both mean and median survival, ranged from
£20,475 to £68,598. The second cost-effectiveness analysis
resulted in ratios ranging from £14,595 to £32,066.
Conclusions: Pemetrexed/cisplatin demonstrated acceptable
cost-effectiveness when compared with cisplatin mono-
therapy and alternative treatments commonly used in UK
clinical practice.
Keywords: cisplatin, cost-effectiveness, malignant pleural
mesothelioma, pemetrexed, United Kingdom.
Introduction
Malignant pleural mesothelioma is an invasive and
generally fatal malignancy of the lung caused by
exposure to asbestos ﬁbers. It is a relatively uncom-
mon cancer in the United Kingdom but has been pre-
dicted to increase in incidence to between 1950 and
2450 deaths per year in the period from 2011 to
2015 [1], accelerating the momentum to seek effec-
tive management.
Survival is poor, reﬂecting both the aggressiveness
of the disease and the clinical challenge of providing
effective management. Surgical and radiotherapy inter-
ventions provide limited survival gains. Reported
phase II single and combination chemotherapeutic
agent studies do not indicate better efﬁcacy than sur-
gical or radiotherapy interventions [2]. A recent phase
III randomized trial has, however, demonstrated the
survival beneﬁt of pemetrexed plus cisplatin over cis-
platin monotherapy [3].
The cost-effectiveness of pemetrexed/cisplatin com-
pared with cisplatin monotherapy, and with a number
of other malignant pleural mesothelioma treatments,
was evaluated in relation to UK clinical practice. A
trial-based model developed from individual patient
data collected from the EMPHACIS randomized clini-
cal trial evaluated the cost-effectiveness of pemetrexed/
cisplatin versus cisplatin (model 1). A second model
(model 2) compared mean costs and outcomes for
malignant pleural mesothelioma patients who were
treated with pemetrexed/cisplatin to other common
clinical practice interventions: MVP (mitomycin-C,
vinblastine and cisplatin); vinorelbine; and active
symptom control.
Cost-effectiveness and cost-utility models were
applied to calculate costs to theNational Health Service
(NHS), the treatment survival beneﬁt in the trial setting,
and the survival beneﬁt indicative of current UK clinical
interventions. Results are presented as both incremental
cost per life-year gained and incremental cost per
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quality-adjusted life-year ratios—survival-based out-
comes that are appropriate in this setting.
Methods
Direct costs associated with pemetrexed/cisplatin and
cisplatin monotherapy, and the incremental survival
outcomes for both trial arms, were calculated using
key data from the phase III trial (model 1). The efﬁcacy
of each trial arm was examined in light of the primary
outcome—survival—in the fully supplemented patient
population and subgroups. The fully supplemented
population was considered most relevant in the eco-
nomic evaluation because the UK product license
stipulates supplementing pemetrexed with folic acid
and vitamin B12.
Survival was examined in the fully supplemented
population, fully supplemented with advanced (stage
III or IV) disease cohort; fully supplemented with good
performance status (PS 0 or 1) cohort; and a cohort
combining advanced disease with good performance
status. Patients in the fully supplemented with good
performance status cohort had Karnofsky perfor-
mance status (KPS) scores of 80 to 100, deﬁning good
performance from, or tolerance to, chemotherapy. KPS
scores in the 80 to 100 range were converted to World
Health Organization performance status scores.
These large cohorts within the fully supplemented
population were evaluated because the decision to
treat would be inﬂuenced by patients who were most
ill and/or able to tolerate chemotherapy. Model 2
established mean costs and outcomes for patients
in the fully supplemented population receiving
pemetrexed/cisplatin that were determined in model 1,
and makes comparisons with common UK interven-
tions identiﬁed through a systematic literature review
and market research of UK physicians. Interventions
included MVP, vinorelbine (either as monotherapy or
in combination), and active symptom control. Despite
the lack of randomized clinical trials evaluating these
treatment options, it was considered important to
supplement the input data for the model. A systematic
review of clinical evidence identiﬁed regimen dosage
and duration, likely adverse event rates, survival out-
comes, and active symptom control.
Although patients with malignant pleural mesothe-
lioma receiving chemotherapy also typically receive
some active symptom control, for the purpose of the
study, it was treated as a stand-alone comparison.
The perspective for these cost analyses was NHS
direct medical costs associated with malignant pleural
mesothelioma treatment. No indirect or social care
costs were incorporated. Unit costs were derived
from NHS Reference Costs, Personal Social Services
Research Unit [4], and drug price lists [5,6].
The time horizon was 29 months, equating to the
length of follow-up in the phase III trial.
Model 1
The economic analysis was based on patients with
malignant pleural mesothelioma who represented UK
norms, and for whom the greatest degree of cost-
effectiveness was demonstrated. The focus was
patients in the fully supplemented phase III trial popu-
lation with advanced (stage III/IV) disease who dem-
onstrated good performance status (PS 0/1) (Fig. 1).
Costs
The fully supplemented patient population were given
folic acid and vitamin B12 during both the baseline and
the treatment periods in accordance with the UK
product license for pemetrexed/cisplatin. Patients were
also supplemented prophylactically with dexametha-
sone to prevent the occurrence of rash as a side effect.
Unit costs were assigned in accordance with
resource use demonstrated in the EMPHACIS trial for
drug acquisition, administration, hospitalization for
disease-related adverse events and events considered
related to the study drug, concomitant medication, and
poststudy chemotherapy (Table 1).
Drug costs were calculated per patient according to
dose, body surface area (BSA), and the number of
cycles administered in the phase III clinical trial. Unit
cost in the base case was calculated by assuming dis-
posal of unused portions of 500-mg pemetrexed vials.
This was varied in the sensitivity analysis to observe
the impact on cost-effectiveness by assuming availabil-
ity of 100-mg pemetrexed vials.
Administration costs were based on both inpatient
and outpatient visits [7] and all adverse event hospi-
talizations were included as resource use. Each
inpatient episode was assigned to the most relevant
health-related group (HRG) [8]. The HRG system cor-
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Figure 1 Intention-to-treat (ITT) population
and subgroups analyzed in economic evaluation.
FS w PS 0/1, fully supplemented, with a perfor-
mance score of 0 or 1; FS w AD, fully supple-
mented, with advanced disease; FS, fully
supplemented; FS w AD & PS 0/1, fully supple-
mented, with advanced disease and a perfor-
mance score of 0 or 1.
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relates inpatient treatments and hospital resources
consumed. Episode costs were applied to account for
cost variations experienced in international trials.
Concomitant medications were vitamin B12, folic
acid, and dexamethasone. Vitamin B12 was adminis-
tered before other therapies, but was grouped as a
concomitant medication for analysis. Folic acid and
dexamethasone costs were calculated as the product of
unit cost, dose, and the mean number of treatment
cycles. Therapeutic compliance was assumed to be
100% for fully supplemented patients.
All chemotherapy administered after completion of
the study treatment regimen (poststudy treatment) was
costed per patient using British National Formulary [5]
and MIMS [6] according to average doses from the
electronic medicines compendium Web site [9]. This
was necessary because although the trial reported regi-
mens administered to patients, poststudy dosing data
were not reported per patient. The generic drug cost
was applied to simulate UK clinical practice norms.
Administration costs were not included.
Outcomes
Kaplan–Meier curves showed the overall survival in
both treatment arms (Fig. 2). Primary analysis of sur-
vival between the trial treatment arms was performed
using Kaplan–Meier nonparametric techniques to
account for high censorship levels (pemetrexed/
cisplatin arm = 44%; cisplatin arm = 32%).
Monthly survival estimates along Kaplan–Meier
curves were noted for each treatment arm to 29 months
(the follow-up period of the phase III trial) with results
representing the mean survival among patients receiv-
ing that treatment at each monthly interval. The differ-
ence in survival between the treatment arms gave a
treatment beneﬁt for each patient population assessed
in the cost-effectiveness analysis. That is, the mean
overall survival in patients treated with pemetrexed/
cisplatin therapy was estimated from the area below the
pemetrexed/cisplatin curve for each population or sub-
group in focus. For the purposes of the economic evalu-
ation, these outcomes are presented as life-years.
Quality-adjusted life-year values were also esti-
mated for mean and median survival. Base case utility
values of 0.68 and 0.69 were applied to the
pemetrexed/cisplatin and cisplatin arms, respectively.
These reﬂect weighted average utility values, calcu-
lated by determining the proportion of patients class-
iﬁed to performance status 0, 1, or 2 in the fully
supplemented population and applying utility values
from the ACTION study [10]. The ACTION study
considered nonsmall cell lung cancer, but extrapola-
tion of its utility scores to health states in this analysis
Table 1 Units costs applied to trial-based resource use (fully supplemented population)
Event/resource Units Mean total cost per patient Source
Pemetrexed
Study arm Year 1 = 500 mg/m2 on day 1 of every
21-day cycle; mean 4.7 cycles
£8148 Manufacturer,
EMPHACIS study
Comparator NA — —
Cisplatin
Study arm Year 1 = 75 mg/m2 on day 1 of every
21-day cycle; mean 4 cycles
£420 [5], EMPHACIS study
Comparator £366
Chemotherapy administration
Study arm (outpatient)
Study arm (inpatient)
All FS patients; day 1 of every
21-day cycle
£2539 [7], EMPHACIS study
Comparator (outpatient)
Comparator (inpatient)
All FS patients; day 1 of every
21-day cycle
£2056
Adverse event hospitalizations
Study arm 70% of all adverse event hospitalizations
occurred in the study arm (63 of 90)
£304 [8], EMPHACIS study
Comparator 30% of all adverse event hospitalizations
occurred in the comparator arm (27 of 90)
£135
Dexamethasone
Study arm All FS patients; 24 mg every 21-day cycle £5.10 [5], EMPHACIS study
Comparator £4.14
Folic acid
Study arm All FS patients; daily dose 400 mg £2.57 [5], EMPHACIS study
Comparator £2.08
Vitamin B12
Study arm All FS patients; vitamin B12 (1 mg/mL
injection) administered 1–3 weeks before
study drug and repeated every 9 weeks
£5.20 [5], EMPHACIS study
Comparator £3.96
Poststudy chemotherapy
Study arm * £1104.53 [5], EMPHACIS study
Comparator £1120.24
*Dosing data for all poststudy chemotherapy regimens was sourced from the Electronic Medicines Compendium, 2005 (http://www.medicines.org.uk).
FS, fully supplemented; NA, not applicable.
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was considered appropriate because of the large
sample size, patient (rather than proxy) completion of
the EQ-5D, and stratiﬁcation by performance status.
The robustness of the cost-effectiveness model was
tested using sensitivity analyses on key variables affect-
ing both cost and outcome estimates. One-way sensi-
tivity analyses assessed the impact of variations in
parameter values and base case assumptions suscep-
tible to degrees of uncertainty that may inﬂuence cost-
effectiveness results. Variables exerting the greatest
inﬂuence on cost-effectiveness were aggregated in a
subsequent two-way sensitivity analysis to further
scrutinize the impact in the fully supplemented popu-
lation and the fully supplemented with advanced
disease patient subgroup.
The greatest inﬂuence on cost-effectiveness and cost
utility ratios resulted from varying the cost of chemo-
therapy by 20%. The greatest impact on outcomes
was demonstrated by modifying survival estimates by
1.5 months on the pemetrexed/cisplatin arm and
using upper and lower conﬁdence intervals (CI)
around the median survival estimate.
Results—Model 1
Total incremental cost associated with pemetrexed/
cisplatin treatment in the phase III trial ranged from
£8779 to £9020 among the targeted population sub-
groups. The subgroup of fully supplemented patients
with performance scores of 0 or 1 was associated with
highest costs.
The discounted average survival gain over
29 months ranged from 0.20 to 0.28 life-years among
all relevant patient subgroups. Patients in the fully
supplemented with advanced disease and performance
score 0/1 subgroup achieved the greatest survival gain.
This group was followed closely by patients in the fully
supplemented with advanced disease subgroup. The
survival gains associated with pemetrexed/cisplatin
therapy, relative to cisplatin, are highly signiﬁcant
patient outcomes. Quality-adjusted mean survival for
all subgroups returned values in the range from 0.13 to
0.20 quality-adjusted life-years. Quality-adjusted sur-
vival was most prolonged in the fully supplemented
with performance score 0/1 patient subgroup.
Median discounted survival gain associated with
pemetrexed/cisplatin therapy relative to cisplatin
therapy over 29 months was higher than the mean and
ranged from 0.26 to 0.44 life years among the relevant
patient subgroups. Quality-adjusted median survival
in all subgroups returned values ranging from 0.17 to
0.31 quality-adjusted life-years. Each patient sub-
group’s total costs were divided by life-years and
quality-adjusted life-years gained, respectively, to
determine incremental costs per life-year and per
quality-adjusted life-year estimates. Cost-effectiveness
ratios were calculated based on both mean and median
survival estimates. Table 2 summarizes the cost-
effectiveness for pemetrexed/cisplatin versus cisplatin
by population subgroup.
Results from the analysis of mean survival indicated
that pemetrexed/cisplatin therapy was most cost-
effective for patients in the performance score 0/1 sub-
groups. Results from the analysis of median survival
indicated that pemetrexed/cisplatin was most cost-
effective for patients in the fully supplemented with
advanced disease subgroup. The incremental cost per
quality-adjusted life-year (mean) was most favorable
for patients in the fully supplemented with perfor-
mance score 0/1 subgroup. Patients in the fully supple-
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Figure 2 Kaplan–Meier estimates of survival time for pemetrexed/cisplatin and cisplatin alone, fully supplemented subgroup.
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mented with advanced disease and performance score
0/1 patient subgroup demonstrated the most cost-
effective cost per quality-adjusted life-year (median)
ratio.
Two-way sensitivity analyses around the fully
supplemented population established that the model
results were sensitive to changes of multiple variables:
In the case of lower survival estimates, pemetrexed/
cisplatin costs per life-year gained and costs per
quality-adjusted life-year became markedly lower. This
effect was enhanced in relation to increasing drug
treatment costs. The lowest costs per life-year gained
were demonstrated where lower 95% CI median sur-
vival data were combined with the 100-mg vial/
batches of pemetrexed scenario. Costs per quality-
adjusted life-year increased relative to reduced survival
for pemetrexed/cisplatin patients. This effect was cor-
roborated when drug treatment costs were increased.
In two-way sensitivity analyses of the fully supple-
mented with advanced disease patient subgroup,
results were also sensitive to changes of multiple vari-
ables: In the case of upper 95% CI around median
survival, costs per life-year gained became markedly
higher. This effect was reinforced when increasing drug
treatment costs were considered. The lowest costs per
life-year gained were demonstrated where lower 95%
CI median survival data combined with a 20% reduc-
tion in the cost of pemetrexed scenario.
Model 2
The fully supplemented patient population (n = 331),
described in model 1, was further examined in model
2. The mean costs and outcomes calculated for fully
supplemented patients treated with pemetrexed/
cisplatin were compared with alternative malignant
pleural mesothelioma treatment options currently used
in the United Kingdom.
Costs
Unit costs were applied to drug acquisition, adminis-
tration, and hospitalization for adverse events. Calcu-
lation of adverse event hospitalization costs assumed
that toxicities occurred only once per patient. Unit
costs were obtained from the British National Formu-
lary [5] and MIMS [6].
The total drug cost of each alternative chemo-
therapy regimen was calculated as a product of the
recommended average dose per patient per cycle (mg/
m2); an assumed 1.8-m2 average BSA (based on phase
III trial data, where average BSA was >1.8 m2, and the
ACTION study [10]); and an assumed mean number
of treatment cycles. Survey results from clinicians
provided the numbers of cycles data. Costs for
pemetrexed/cisplatin were calculated as for model 1.
Drugs were administered on inpatient and out-
patient bases. The proportion of inpatient versus out-
patient administration for MVP and vinorelbine
(platinum) was assumed to be similar to pemetrexed/
cisplatin and cisplatin treatment arms in the clinical
trial (62.7% inpatient; 37.3% outpatient) on the basis
that platinum administration is more resource-
intensive than other agents. Administration costs were
based on NHS Reference Costs 2004 [8].
Costs calculations assumed that patients received
one course of chemotherapy in the 12-month period,
consistent with the model 1 methodology. Scant evi-
dence in the literature concerning chemotherapy
administered after MVP or vinorelbine  platinum
regimen informed the decision to exclude costs of post-
study chemotherapy in model 2. Hospital episode costs
for adverse events were based on NHS Reference Costs
2004 [8] and costing methods remained consistent
with model 1. A dearth of literature-based resource use
information, particularly concerning adverse events
and hospitalization data, required supplementation by
market research survey results. Published toxicity rates
and the survey results were compared, and a non-
weighted mean value was included in the model. A unit
cost consistent with model 1 was applied: Each event
was linked to an NHS Reference Cost episode. A con-
servative assumption was made that each adverse
event was associated with only one hospital episode.
Most reported grade 3 and 4 toxicities require hos-
pitalization. However, grade 3 neutropenia can occur
without requiring hospitalization. Calculations using
trial data determined that 30% of patients with grade
Table 2 Summary of cost-effectiveness for pemetrexed/cisplatin versus cisplatin by population subgroup
Increment
Fully
supplemented
Fully
supplemented
with advanced
disease
Fully supplemented
with performance
score 0/1
Fully
supplemented
with advanced
disease and
performance
score PS 0/1
Incremental cost per life-year (mean) £44,264 £35,065 £31,688 £31,337
Incremental cost per life-year (median) £34,433 £21,948 £30,511 £20,475
Incremental cost per QALY (mean) £68,599 £53,314 £45,454 £44,950
Incremental cost per QALY (median) £52,188 £35,158 £43,663 £29,044
QALY, quality-adjusted life-year.
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3 or 4 toxicities have grade 4 neutropenia and require
hospitalization. A factor of 30% was applied to the
reported incidence of neutropenia in the literature
when grade 3 and 4 toxicities were reported together.
It was assumed that patients with leukopenia did not
require hospitalization and that incidence of reported
leukopenia was linked to its status as a neutropenia
blood marker.
Model 2 assumed zero costs for active symptom
control in consideration that it is a component of
chemotherapy administration [11]. The type of active
symptom control provided in the phase III trial, the
MVP clinical trials [12,13], and the vinorelbine clinical
trials [14,15] was not reported consistently. Hence, it
was assumed that all patients received similar levels of
supportive care, irrespective of chemotherapy regimen.
On this basis, the cost of active symptom control has
no impact on incremental costs, and the value is zero.
A literature review of active symptom control/best sup-
portive care cost identiﬁed a wide range of variations
in the cost estimates and descriptions of active
symptom control, further supporting the assumptions
made.
Outcomes
The primary outcome was survival. Given that the
literature presents only median survival estimates and
survival probabilities, an exponential distribution was
assumed for treatment options in the absence of actual
data. Survival times were assumed to follow an expo-
nential distribution of the form
exp ; ln .−( ) ∗x mean value is , and the medianβ β β2 (1)
The sample sizes reporting median survival times
for MVP and vinorelbine were typically very small,
and Kaplan–Meier survival curves were frequently
absent. With no access to data from these trials to test
the assumption that an exponential survival distribu-
tion holds, the following factor was assumed to enable
the estimation of mean survival from the median:
mean median calculated from fully
supplemented mean f
= ∗ (1 24
12 40
.
. ully supplemented
median 10 0 1 24. . .= ) (2)
To calculate quality-adjusted life-years, and in the
absence of mesothelioma-speciﬁc literature, utility
values for advanced cancer were derived from a review
of nonsmall cell lung cancer literature. The utility
scores from ACTION for each performance score
group were applied to the malignant pleural mesothe-
lioma data. The same utility values were applied to all
treatment arms, including active symptom control,
although pemetrexed/cisplatin showed signiﬁcantly
better symptom relief and quality of life in the trial [3].
The only differentiation made was performance score,
because high-performance patients were proved to
have better quality of life than patients with low per-
formance status. The same proportions of patients
with performance scores of 0, 1, and 2 were assumed
for the comparator arms MVP, vinorelbine, and active
symptom control as for the pemetrexed/cisplatin arm.
Estimates were altered in sensitivity analyses within
the ranges reported in the literature and by ACTION.
MVP
Mitomycin-C, vinblastine, and cisplatin (MVP) treat-
ment median survival data [12,13], which informed
calculation of a weighted median, was converted into
the mean, and then discounted, with consideration
given to the reported survival function over time. The
calculated discounted mean survival time associated
with MVP treatment is 0.698 life-years per patient.
Vinorelbine
The reported median survival time for vinorelbine
monotherapy (10.6 months) and a 1-year survival rate
of 41% [14] were considered. Further survival rates
were not reported. It was therefore assumed that
vinorelbine  platinum treatment strategies were at
least as effective as cisplatin, and the cisplatin mono-
therapy survival estimates for the fully supplemented
population in the phase III trial were utilized (2-year
survival 17%).
Active Symptom Control
Active symptom control offers only a small survival
beneﬁt to patients (0.082 life-years). It is associated
with very low survival rates over time—1-year sur-
vival, 8%; 2-year survival, 2% [16,17].
Results—Model 2
The total mean cost of treating a patient with
pemetrexed/cisplatin was £11,410 compared with
£3806 for MVP-treated patients. Vinorelbine was
more costly than MVP at a total treatment cost per
patient of £7662. Active symptom control was
assumed to have a zero cost in the model.
The model estimated a survival gain associated with
pemetrexed/cisplatin of 0.521 life-years (1.219–0.698)
and 0.350 quality-adjusted life-years (0.830–0.480)
when compared with MVP. The estimated survival
gain associated with pemetrexed/cisplatin when
compared with vinorelbine was 0.218 life-years
(1.219–1.001) and 0.142 quality-adjusted life-years
(0.830–0.689); comparison with active symptom
control resulted in 0.530 life-years (1.219–0.690) and
0.356 quality-adjusted life-years (0.830–0.475). The
ﬁgures in parentheses represent life-years, or quality-
adjusted life-years, associated with pemetrexed/
cisplatin versus each respective comparator. The
difference between the values represents the incremen-
tal survival gain associated with pemetrexed/cisplatin
(Table 3).
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Sensitivity Analysis
MVP
The one-way sensitivity analyses showed that the
incremental costs per life-year gained/per quality-
adjusted life-year are slightly sensitive to the applied
changes. Survival estimates showed the strongest inﬂu-
ence, particularly when modeled according to a
Weibull distribution, and consequently, were com-
bined with a second variable in a two-way sensitivity
analysis. Here, costs per life-year gained become
higher in the case of lowered survival estimates for the
comparator strategies, and changing drug administra-
tion patterns. Using median survival data instead of
several mean survival data scenarios caused the largest
changes in costs per life-year gained. Conversely, costs
per life-year gained decreased when survival was
modeled according to a Weibull distribution. The cost
per life-year gained further decreased when the shape
parameter associated with the Weibull distribution was
increased while holding the scale [1/(1.24*median)]
constant. Costs per life-year gained also decreased
markedly in the case of increasing proportions of inpa-
tient drug administration services. This was caused by
a lowered cost difference between pemetrexed/cisplatin
and MVP treatment.
Costs per quality-adjusted life-years showed sensi-
tivity associated with the Weibull distribution around
survival. Sensitivity was limited, although pronounced
in inpatient drug administration for all patients, while
costs per quality-adjusted life-year became markedly
lower.
Vinorelbine
One-way sensitivity analyses showed that modeling
survival estimates according to a Weibull distribution
had the greatest inﬂuence on cost per life-year and cost
per quality-adjusted life-year results. Reducing the
number of treatment cycles also showed an impact.
Two-way sensitivity demonstrated that the model
results were sensitive to lower or median survival
estimates for the comparator strategies (vinorelbine
 platinum), with costs per life-year gained as well as
costs per quality-adjusted life-year becoming markedly
lower. This effect was strengthened where drug treat-
ment costs and drug administration patterns were
changed. The lowest costs per life-year gained were
demonstrated when median survival data was com-
bined with all drug administration services provided
on an inpatient basis.
Costs per quality-adjusted life-year became lower in
the case of lowered survival ﬁgures for the comparator
treatment approaches. This effect was strengthened
when drug treatment and administration costs were
changed, particularly if drug treatment costs increased
or if drug administration was provided on an inpatient
basis only.
Active Symptom Control
The results of a review reporting UK average costs of
£3342 per non–small cell lung cancer patient treated
with best supportive care [18] were considered for the
sensitivity analysis comparing pemetrexed/cisplatin
and active symptom control. This study also reported
on the costs per patient treated with vinorelbine
(£3963 per patient) or vinorelbine + cisplatin (£4736)
[18]. The ﬁndings are quite comparable with the costs
examined in this model (£4454), and therefore they
were considered in the following sensitivity analysis.
Cost-effectiveness became markedly reduced with
change in a few variables in two-way sensitivity analy-
Table 3 Cost-effectiveness for pemetrexed/cisplatin versus alternative comparators
Pemetrexed/cisplatin MVP Incremental gain
Costs* £11,410 £3,806 £7,604
Life years gained (mean) 1.219 0.698 0.521
Incremental cost per life-year £14,595
QALYs per patient 0.830 0.480 0.350
Incremental cost per QALY £21,731
Pemetrexed/cisplatin Vinorelbine platinum† Incremental gain
Costs* £11,410 £7,662 £3,748
Life-years gained (mean) 1.219 1.001 0.218
Incremental cost per life-year £17,156
QALYs per patient 0.830 0.689 0.142
Incremental cost per QALY £26,437
Pemetrexed/cisplatin Active symptom control Increment gain
Costs* £11,410 £0 £11,410
Life-years (mean) 1.219 0.690 0.530
Incremental cost per life-year £21,545
QALYs per patient 0.830 0.475 0.356
Incremental cost per QALY £32,066
*In the absence of compliance data, an assumption of 100% compliance with all drugs per cycle was made. †Mean costs for the different treatment strategies using vinorelbine
were weighted by their relative frequencies reported during the UK survey: Out of all patients treated with vinorelbine, monotherapy was reported to be used in 80% of cases,
vinorelbine/cisplatin in 11.7% of cases, and vinorelbine/carboplatin in 8.3% of cases. Considering this distribution, the overall mean costs per patient treated with
vinorelbine platinum were calculated to be £7662 [(80% ¥ £8004.78) + (11.7% ¥ £5890.64) + (8.3% ¥ £6854.20)].
Note: Numbers may not add up because of rounding.
MVP, mitocmycin-c, vinblastine, cisplatin; QALY(s); quality-adjusted life-year(s).
10 Cordony et al.
sis: The applied changes of survival input data and
costs for active symptom control caused reductions of
costs per life-year gained and per quality-adjusted life-
year. This reduction was offset if the discount rate was
increased to 6% for the costs per quality-adjusted life-
year. Conversely, the costs per life-year beneﬁted from
lower discount rates, as shown by applying a zero
discount rate.
Discussion
This study has demonstrated that pemetrexed/cisplatin
is a cost-effective alternative to cisplatin to treat
patients with malignant pleural mesothelioma. Eco-
nomic analysis around the randomized phase III trial
of pemetrexed/cisplatin versus cisplatin alone has
shown a clear survival gain for all patients in the
intention-to-treat population. The prolonged survival
demonstrated in fully supplemented patients with
advanced (stage III/IV) disease, fully supplemented
patients with good performance status (PS 0/1), and
fully supplemented patients with advanced disease and
good performance status are perhaps more signiﬁcant
within UK clinical practice because these are the
patients who reﬂect anticipated use of pemetrexed/
cisplatin.
Importantly, the survival achieved by patients
receiving pemetrexed/cisplatin did not appear to be
impaired by additional toxicity in the combination
arm, as demonstrated by the quality of life and
symptom beneﬁt results. This is also evident in the
fully supplemented advanced disease subgroup of
patients, despite greater severity of disease. In consid-
eration of the nature of the disease, and the side effects
associated with alternative chemotherapy agents, these
are signiﬁcant advantages.
Considering only the average gain in patient sur-
vival, the incremental cost per life-year gained with the
study treatment falls in the range from £31,337 to
£44,264, with patients in the fully supplemented with
advanced disease, performance score 0/1 cohort
achieving the most positive result. In comparison, the
incremental cost per quality-adjusted life-years gained
ratios ranged from £44,950 to £68,598. Despite being
slightly higher, these ratios could be considered cost-
effective by the UK reimbursement authority (National
Institute for Health and Clinical Excellence) because
they reﬂect survival gains as well as therapeutic gains
in quality of life. Improvements in both are rarely
achieved by many chemotherapeutic treatments
because of their highly toxic nature.
Analysis of alternative therapies currently used to
treat malignant pleural mesothelioma in the UK setting
(MVP, vinorelbine, and active symptom control)
also demonstrated favorable cost-effectiveness. Results
indicated the expected level of incremental cost and
beneﬁt for each treatment comparison and the likely
cost-effectiveness of pemetrexed/cisplatin in UK clini-
cal practice. Absence of phase III clinical trials for
current malignant pleural mesothelioma chemothe-
rapy regimens meant that the quality of evidence was
compromised when compared with direct trial-based
comparisons of cisplatin. Conservative estimates and
assumptions favoring the comparator sought to offset
these data limitations.
Pemetrexed/cisplatin therapy has several
advantages—prolonged survival, good tolerability, a
manageable administration schedule, limited toxicity
when compared with cytotoxics of similar potency
[19], and no negative impact of toxicity on patient
quality of life [20]. The introduction of pemetrexed
into the current mix of cytotoxics available in UK
clinical practice is therefore unlikely to have a clinical
burden. The pemetrexed/cisplatin combination could
also be considered a cost-effective treatment when
compared with cisplatin monotherapy, or any of MVP,
vinorelbine, and active symptom control that are cur-
rently used to treat malignant pleural mesothelioma in
the United Kingdom.
The major limitation of pemetrexed/cisplatin
therapy is the high cost associated with the study drug.
The cost primarily drives the cost-effectiveness results
presented here. When compared with other commonly
used therapy options for the treatment of malignant
pleural mesothelioma in UK clinical practice, the cost
of pemetrexed/cisplatin is almost three times as much
as one alternative. The UK health system would incur
additional costs if patients were switched from other
less effective, less costly regimens to pemetrexed/
cisplatin. Nevertheless, although the number of malig-
nant pleural mesothelioma patients is increasing, the
population remains relatively small and the economic
burden of switching patients is not expected to be
large.
In view of the fact that malignant pleural mesothe-
lioma is an orphan disease with no licensed or proven
alternative to active symptom control in the United
Kingdom, any treatment achieving better survival out-
comes and improvements in quality-of-life (relative to
cost) for patients is likely to be thoughtfully consid-
ered. Given the less effective comparators, pemetrexed/
cisplatin is the logical and cost-effective chemotherapy
treatment option for patients with advanced malignant
pleural mesothelioma in the United Kingdom.
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